APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Balancing Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hormone Balancing Therapy Market Outlook and Growth Opportunities 2026

2 May 2026199 pages

Choose your research edition.

Industry ResearchHormone Balancing Therapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Balancing Therapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hormone Balancing Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Balancing Therapy Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Balancing Therapy Market Analysis and Forecast 2026-2032258 pages · $4,950 USD

Market perspective

The global Hormone Balancing Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hormone Balancing Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hormone Balancing Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hormone Balancing Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hormone Balancing Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hormone Balancing Therapy market include Pfizer, Novartis, Merck, AbbVie, Bayer, Eli Lilly and Company, Allergan, Amgen and TherapeuticsMD, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hormone Balancing Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hormone Balancing Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hormone Balancing Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hormone Balancing Therapy market.

Hormone Balancing Therapy Segment by Company

Pfizer

Novartis

Merck

AbbVie

Bayer

Eli Lilly and Company

Allergan

Amgen

TherapeuticsMD

Endo International

Hormone Balancing Therapy Segment by Type

Estrogen Therapy

Progesterone Treatment

Combination Therapy

Other

Hormone Balancing Therapy Segment by Application

Female

Male

Hormone Balancing Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hormone Balancing Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hormone Balancing Therapy key companies, revenue, market share, and recent developments.

3. To split the Hormone Balancing Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hormone Balancing Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hormone Balancing Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Hormone Balancing Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Balancing Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Balancing Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Balancing Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hormone Balancing Therapy industry.

Chapter 3: Detailed analysis of Hormone Balancing Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hormone Balancing Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hormone Balancing Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hormone Balancing Therapy Industry Trends Table 2. Hormone Balancing Therapy Industry Drivers Table 3. Hormone Balancing Therapy Industry Opportunities and Challenges Table 4. Hormone Balancing Therapy Industry Restraints Table 5. Global Hormone Balancing Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hormone Balancing Therapy Revenue Share by Company (2021-2026) Table 7. Global Hormone Balancing Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hormone Balancing Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Hormone Balancing Therapy Company, Product Type & Application Table 10. Global Hormone Balancing Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hormone Balancing Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Estrogen Therapy Table 15. Significant Companies of Progesterone Treatment Table 16. Significant Companies of Combination Therapy Table 17. Significant Companies of Other Table 18. Global Hormone Balancing Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Hormone Balancing Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Hormone Balancing Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Hormone Balancing Therapy Sales Value Share by Type (2021-2026) Table 22. Global Hormone Balancing Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Female Table 24. Significant Companies of Male Table 25. Global Hormone Balancing Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hormone Balancing Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Hormone Balancing Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Hormone Balancing Therapy Sales Value Share by Application (2021-2026) Table 29. Global Hormone Balancing Therapy Sales Value Share by Application (2027-2032) Table 30. Global Hormone Balancing Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Hormone Balancing Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Hormone Balancing Therapy Sales Value Share by Region (2021-2026) Table 33. Global Hormone Balancing Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Hormone Balancing Therapy Sales Value Share by Region (2027-2032) Table 35. Global Hormone Balancing Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Hormone Balancing Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Hormone Balancing Therapy Sales Value Market Share by Country (2021-2026) Table 38. Global Hormone Balancing Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Hormone Balancing Therapy Sales Value Market Share by Country (2027-2032) Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Pfizer Hormone Balancing Therapy Product Portfolio Table 44. Pfizer Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis Hormone Balancing Therapy Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Merck Hormone Balancing Therapy Product Portfolio Table 54. Merck Recent Development Table 55. AbbVie Company Information Table 56. AbbVie Business Overview Table 57. AbbVie Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. AbbVie Hormone Balancing Therapy Product Portfolio Table 59. AbbVie Recent Development Table 60. Bayer Company Information Table 61. Bayer Business Overview Table 62. Bayer Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Bayer Hormone Balancing Therapy Product Portfolio Table 64. Bayer Recent Development Table 65. Eli Lilly and Company Company Information Table 66. Eli Lilly and Company Business Overview Table 67. Eli Lilly and Company Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Eli Lilly and Company Hormone Balancing Therapy Product Portfolio Table 69. Eli Lilly and Company Recent Development Table 70. Allergan Company Information Table 71. Allergan Business Overview Table 72. Allergan Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Allergan Hormone Balancing Therapy Product Portfolio Table 74. Allergan Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Amgen Hormone Balancing Therapy Product Portfolio Table 79. Amgen Recent Development Table 80. TherapeuticsMD Company Information Table 81. TherapeuticsMD Business Overview Table 82. TherapeuticsMD Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. TherapeuticsMD Hormone Balancing Therapy Product Portfolio Table 84. TherapeuticsMD Recent Development Table 85. Endo International Company Information Table 86. Endo International Business Overview Table 87. Endo International Hormone Balancing Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Endo International Hormone Balancing Therapy Product Portfolio Table 89. Endo International Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Hormone Balancing Therapy Product Image Figure 2. Global Hormone Balancing Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hormone Balancing Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Hormone Balancing Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Estrogen Therapy Image Figure 8. Progesterone Treatment Image Figure 9. Combination Therapy Image Figure 10. Other Image Figure 11. Global Hormone Balancing Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Hormone Balancing Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Hormone Balancing Therapy Sales Value Share by Type (2021-2032) Figure 14. Female Image Figure 15. Male Image Figure 16. Global Hormone Balancing Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Hormone Balancing Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Hormone Balancing Therapy Sales Value Share by Application (2021-2032) Figure 19. Global Hormone Balancing Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Hormone Balancing Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Hormone Balancing Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. North America Hormone Balancing Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Hormone Balancing Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Hormone Balancing Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Hormone Balancing Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Hormone Balancing Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Hormone Balancing Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. South America Hormone Balancing Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Hormone Balancing Therapy Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Hormone Balancing Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Hormone Balancing Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Estrogen Therapy
  • Progesterone Treatment
  • Combination Therapy
  • Other
Applications
  • Female
  • Male
Companies covered
  • Pfizer
  • Novartis
  • Merck
  • AbbVie
  • Bayer
  • Eli Lilly and Company
  • Allergan
  • Amgen
  • TherapeuticsMD
  • Endo International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hormone Balancing Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hormone Balancing Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hormone Balancing Therapy Market Dynamics
  1. 2.1 Hormone Balancing Therapy Industry Trends
  2. 2.2 Hormone Balancing Therapy Industry Drivers
  3. 2.3 Hormone Balancing Therapy Industry Opportunities and Challenges
  4. 2.4 Hormone Balancing Therapy Industry Restraints
3 Hormone Balancing Therapy Market by Company
  1. 3.1 Global Hormone Balancing Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Hormone Balancing Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Hormone Balancing Therapy Company Ranking (2024-2026)
  4. 3.4 Global Hormone Balancing Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Hormone Balancing Therapy Company Product Type and Application
  6. 3.6 Global Hormone Balancing Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hormone Balancing Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hormone Balancing Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hormone Balancing Therapy Market by Type
  1. 4.1 Hormone Balancing Therapy Type Introduction
  2. 4.1.1 Estrogen Therapy
  3. 4.1.2 Progesterone Treatment
  4. 4.1.3 Combination Therapy
  5. 4.1.4 Other
  6. 4.2 Global Hormone Balancing Therapy Sales Value by Type
  7. 4.2.1 Global Hormone Balancing Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Hormone Balancing Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Hormone Balancing Therapy Sales Value Share by Type (2021-2032)
5 Hormone Balancing Therapy Market by Application
  1. 5.1 Hormone Balancing Therapy Application Introduction
  2. 5.1.1 Female
  3. 5.1.2 Male
  4. 5.2 Global Hormone Balancing Therapy Sales Value by Application
  5. 5.2.1 Global Hormone Balancing Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hormone Balancing Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Hormone Balancing Therapy Sales Value Share by Application (2021-2032)
6 Hormone Balancing Therapy Regional Value Analysis
  1. 6.1 Global Hormone Balancing Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hormone Balancing Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hormone Balancing Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hormone Balancing Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hormone Balancing Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Hormone Balancing Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hormone Balancing Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Hormone Balancing Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hormone Balancing Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hormone Balancing Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hormone Balancing Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Hormone Balancing Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hormone Balancing Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hormone Balancing Therapy Sales Value Share by Country, 2025 VS 2032
7 Hormone Balancing Therapy Country-level Value Analysis
  1. 7.1 Global Hormone Balancing Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hormone Balancing Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hormone Balancing Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hormone Balancing Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hormone Balancing Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hormone Balancing Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hormone Balancing Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Hormone Balancing Therapy Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Hormone Balancing Therapy Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Hormone Balancing Therapy Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Hormone Balancing Therapy Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Hormone Balancing Therapy Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Hormone Balancing Therapy Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Hormone Balancing Therapy Product Portfolio
  42. 8.7.5 Allergan Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Hormone Balancing Therapy Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 TherapeuticsMD
  50. 8.9.1 TherapeuticsMD Company Information
  51. 8.9.2 TherapeuticsMD Business Overview
  52. 8.9.3 TherapeuticsMD Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 TherapeuticsMD Hormone Balancing Therapy Product Portfolio
  54. 8.9.5 TherapeuticsMD Recent Developments
  55. 8.10 Endo International
  56. 8.10.1 Endo International Company Information
  57. 8.10.2 Endo International Business Overview
  58. 8.10.3 Endo International Hormone Balancing Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Endo International Hormone Balancing Therapy Product Portfolio
  60. 8.10.5 Endo International Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst